These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 31667718

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients.
    van Vliet K, van Ginkel WG, Jahja R, Daly A, MacDonald A, De Laet C, Vara R, Rahman Y, Cassiman D, Eyskens F, Timmer C, Mumford N, Bierau J, van Hasselt PM, Gissen P, Goyens PJ, McKiernan PJ, Wilcox G, Morris AAM, Jameson EA, Huijbregts SCJ, van Spronsen FJ.
    Orphanet J Rare Dis; 2019 Dec 04; 14(1):285. PubMed ID: 31801588
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.
    Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, Sarles J, de Baulny HO, Touati G.
    J Inherit Metab Dis; 2008 Feb 04; 31(1):81-7. PubMed ID: 18214711
    [Abstract] [Full Text] [Related]

  • 9. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC.
    Thimm E, Richter-Werkle R, Kamp G, Molke B, Herebian D, Klee D, Mayatepek E, Spiekerkoetter U.
    J Inherit Metab Dis; 2012 Mar 04; 35(2):263-8. PubMed ID: 22069142
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
    Holme E, Lindstedt S.
    J Inherit Metab Dis; 1998 Aug 04; 21(5):507-17. PubMed ID: 9728331
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Corneal opacities associated with NTBC treatment.
    Ahmad S, Teckman JH, Lueder GT.
    Am J Ophthalmol; 2002 Aug 04; 134(2):266-8. PubMed ID: 12140036
    [Abstract] [Full Text] [Related]

  • 15. Dietary Considerations in Tyrosinemia Type I.
    van Spronsen FJ, van Rijn M, Meyer U, Das AM.
    Adv Exp Med Biol; 2017 Aug 04; 959():197-204. PubMed ID: 28755197
    [Abstract] [Full Text] [Related]

  • 16. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
    Halac U, Dubois J, Mitchell GA.
    Adv Exp Med Biol; 2017 Aug 04; 959():75-83. PubMed ID: 28755185
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tyrosinemia type I: Case series with response to treatment to NTBC.
    Shah I, Shah F.
    Indian J Gastroenterol; 2016 May 04; 35(3):229-31. PubMed ID: 27109516
    [Abstract] [Full Text] [Related]

  • 19. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J, Vilaseca Buscà MA, Lambruschini Ferri N, Mas Comas A, González Pascual E, Holme E.
    An Esp Pediatr; 2001 Mar 04; 54(3):305-9. PubMed ID: 11262262
    [Abstract] [Full Text] [Related]

  • 20. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
    Nobili V, Jenkner A, Francalanci P, Castellano A, Holme E, Callea F, Dionisi-Vici C.
    Pediatrics; 2010 Jul 04; 126(1):e235-8. PubMed ID: 20547648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.